Please login to the form below

Not currently logged in


This page shows the latest Jakafi news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD

FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD

GVHD. In this trial, Jakafi-treated patients experienced significantly greater overall response rates (ORR) compared to BAT at week 24. ... With a priority review in hand, the review of Jakafi in chronic GVHD is shortened to six months, compared to ten

Latest news

More from news
Approximately 6 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...